UCB SA (OTCMKTS:UCBJF – Get Free Report) shares saw unusually-strong trading volume on Thursday . Approximately 4,457 shares changed hands during trading, an increase of 552% from the previous session’s volume of 684 shares.The stock last traded at $274.6875 and had previously closed at $271.6875.
UCB Stock Down 2.3%
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average is $293.04 and its two-hundred day moving average is $300.67.
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
Read More
- Five stocks we like better than UCB
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
- MarketBeat Week in Review – 07/13- 07/17
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
